These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 23160971)

  • 1. Exploring the relationships between scaled bioequivalence limits and within-subject variability.
    Symillides M; Karalis V; Macheras P
    J Pharm Sci; 2013 Jan; 102(1):296-301. PubMed ID: 23160971
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the reference scaled bioequivalence semi-replicate method with other approaches: focus on human exposure to drugs.
    Karalis V; Symillides M; Macheras P
    Eur J Pharm Sci; 2009 Aug; 38(1):55-63. PubMed ID: 19524039
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the bioequivalence of highly-variable drugs and drug products.
    Tothfalusi L; Endrenyi L; Midha KK; Rawson MJ; Hubbard JW
    Pharm Res; 2001 Jun; 18(6):728-33. PubMed ID: 11474774
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Consumer's risk in the EMA and FDA regulatory approaches for bioequivalence in highly variable drugs.
    Muñoz J; Alcaide D; Ocaña J
    Stat Med; 2016 May; 35(12):1933-43. PubMed ID: 26707698
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Limits for the scaled average bioequivalence of highly variable drugs and drug products.
    Tothfalusi L; Endrenyi L
    Pharm Res; 2003 Mar; 20(3):382-9. PubMed ID: 12669957
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of a scaling approach for the bioequivalence of highly variable drugs.
    Haidar SH; Makhlouf F; Schuirmann DJ; Hyslop T; Davit B; Conner D; Yu LX
    AAPS J; 2008 Sep; 10(3):450-4. PubMed ID: 18726698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Controlling type I error in the reference-scaled bioequivalence evaluation of highly variable drugs.
    Ocaña J; Muñoz J
    Pharm Stat; 2019 Oct; 18(5):583-599. PubMed ID: 31190418
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An approach for widening the bioequivalence acceptance limits in the case of highly variable drugs.
    Boddy AW; Snikeris FC; Kringle RO; Wei GC; Oppermann JA; Midha KK
    Pharm Res; 1995 Dec; 12(12):1865-8. PubMed ID: 8786957
    [TBL] [Abstract][Full Text] [Related]  

  • 9. On the leveling-off properties of the new bioequivalence limits for highly variable drugs of the EMA guideline.
    Karalis V; Symillides M; Macheras P
    Eur J Pharm Sci; 2011 Nov; 44(4):497-505. PubMed ID: 21945487
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bioequivalence: switchability and scaling.
    Midha KK; Rawson MJ; Hubbard JW
    Eur J Pharm Sci; 1998 Apr; 6(2):87-91. PubMed ID: 9795020
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Viewpoint: observations on scaled average bioequivalence.
    Patterson SD; Jones B
    Pharm Stat; 2012; 11(1):1-7. PubMed ID: 22162308
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mean difference vs. variability reduction: tradeoffs in aggregate measures for individual bioequivalence. FDA Individual Bioequivalence Working Group.
    Hauck WW; Chen ML; Hyslop T; Patnaik R; Schuirmann D; Williams R
    Int J Clin Pharmacol Ther; 1996 Dec; 34(12):535-41. PubMed ID: 8996848
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inflation of the type I error: investigations on regulatory recommendations for bioequivalence of highly variable drugs.
    Wonnemann M; Frömke C; Koch A
    Pharm Res; 2015 Jan; 32(1):135-43. PubMed ID: 25033764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Likelihood approach for evaluating bioequivalence of highly variable drugs.
    Du L; Choi L
    Pharm Stat; 2015; 14(2):82-94. PubMed ID: 25408492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Scaling or wider bioequivalence limits for highly variable drugs and for the special case of C(max).
    Tothfalusi L; Endrenyi L; Midha KK
    Int J Clin Pharmacol Ther; 2003 May; 41(5):217-25. PubMed ID: 12776813
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bio-International 92, conference on bioavailability, bioequivalence, and pharmacokinetic studies.
    Blume HH; Midha KK
    J Pharm Sci; 1993 Nov; 82(11):1186-9. PubMed ID: 7904641
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel scaled bioequivalence limits with leveling-off properties.
    Kytariolos J; Karalis V; Macheras P; Symillides M
    Pharm Res; 2006 Nov; 23(11):2657-64. PubMed ID: 17048119
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bioequivalence approaches for highly variable drugs and drug products.
    Haidar SH; Davit B; Chen ML; Conner D; Lee L; Li QH; Lionberger R; Makhlouf F; Patel D; Schuirmann DJ; Yu LX
    Pharm Res; 2008 Jan; 25(1):237-41. PubMed ID: 17891552
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of the upper sample size limit in two-stage bioequivalence designs.
    Karalis V
    Int J Pharm; 2013 Nov; 456(1):87-94. PubMed ID: 23954235
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Considerations for metabolite pharmacokinetic data in bioavailability/bioequivalence assessments. Overview of the recent trends.
    Srinivas NR
    Arzneimittelforschung; 2009; 59(4):155-65. PubMed ID: 19517891
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.